Back to Journals » Journal of Asthma and Allergy » Call For Papers

Journal of Asthma and Allergy

ISSN: 1178-6965


The following Article Collections/ Thematic Series are currently open for submissions:

Atopic Dermatitis and Other Atopic Comorbidities

Dove Medical Press is pleased to invite you to submit your research to the upcoming Article Collection “Atopic Dermatitis and Other Atopic Comorbidities” in the Journal of Asthma and Allergy.

Atopic dermatitis (AD) is a chronic inflammatory cutaneous disorder. Currently, AD has been found to be associated with substantial patient burden and numerous atopic comorbidities, including asthma, allergic rhinitis, food allergy, and eosinophilic esophagitis, as well as nonatopic comorbidities, including allergic contact dermatitis, anxiety, depression, suicidality, infections, and cardiovascular disease. All these comorbidities led to the recognition of AD as a systemic disease. Of note, the relationship between AD and comorbidities is likely bidirectional and multifactorial, as well as some comorbidities may be secondary to the effects of the burden of chronic AD.

This Article Collection aims to explore the association between atopic dermatitis and other atopic comorbidities, shedding light on the shared pathophysiological mechanisms and the implications for clinical management.

This Article Collection aims to bring together original research articles, review articles, and commentaries exploring the pathogenesis of atopic diseases, also considering primary immune defects presenting as AD, the role of environmental factors, the impact of environmental allergies and infections, novel diagnostic approaches (including biomarkers), and emerging therapeutic approaches (including biologic treatments and JAK inhibitors). Articles regarding all the atopic diseases (asthma, food allergy, allergic rhinitis, eosinophilic esophagitis, and atopic dermatitis) are welcome.

Potential topics include the following aspects:
- Epidemiology and burden of atopic comorbidities
- Pathophysiological mechanisms
- The role of environmental allergies in atopic diseases
- Biomarkers in atopic diseases
- Asthma and allergic rhinitis in atopic dermatitis
- Atopic dermatitis and food allergies
- Atopic dermatitis and mental health
- Novel therapeutic approaches
- The use of biologics in atopic diseases
- Clinical management and guidelines

All manuscripts submitted to this Article Collection will undergo desk assessment and peer-review as part of our standard editorial process. Guest Advisors for this collection will not be involved in peer-reviewing manuscripts unless they are an existing member of the Editorial Board. Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript.

The deadline for submissions is 19 April 2024.

Please submit your manuscript on our website, quoting the promo code DFHHN to indicate that your submission is for consideration in this Article Collection.

Guest Advisors
Maddalena Napolitano, Professor, MD, Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
[email protected]

Luca Potestio, MD, Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
[email protected]

Cataldo Patruno, Professor, MD, Department of Health Sciences, University Magna Graecia of Catanzaro, Catanzaro
[email protected]

View all papers in this article collection

From Guts to Lungs: Understanding Microbiome Dynamics in Respiratory Health

Dove Medical Press is pleased to invite you to submit your research to the upcoming Article Collection “From Guts to Lungs: Understanding Microbiome Dynamics in Respiratory Health” in the Journal of Asthma and Allergy.

Globally, chronic respiratory diseases pose a major public health problem. In 2017, chronic respiratory diseases attributed to approximately 3.91 million (7%) of worldwide deaths. Common chronic diseases of the upper and lower respiratory tract include cystic fibrosis (CF), chronic rhinosinusitis (CRS), asthma, and chronic obstructive pulmonary disorder (COPD). These diseases affect individuals differentially across the lifespan. 

CF is caused by genetic mutations to the CFTR gene. Recent advances in CFTR modulating therapeutics have improved patient’s quality of life and lifespan. More than half of the CF population is age 18 or older. Childhood asthma contributes to significant morbidity worldwide, and incidence is increasing, particularly in industrialized populations. CRS is a major cause of morbidity in the adult population, affecting between 5%-10% of adults. COPD, the third leading cause of death in the United States, is typically diagnosed later in adulthood, though early onset COPD may be more common than previously recognized. 

Though not an exhaustive list, these chronic diseases present a significant burden to patients and the healthcare system. Risk factors for onset or severity tend to include environment and sociodemographic factors that have an impact on gut and respiratory microbiome composition and function. The host microbiome, or the trillions of microbes that colonize distinct body sites, has a critical role in health status. Studies of the gut microbiome in respiratory disease demonstrate that gut microbiota are critical modulators of inflammatory pathways in the airways, and this can be influenced by environmental factors, such as diet. It is critical to understand 1) how microbiome-host interactions contribute to chronic inflammation in the upper and lower airways, and 2) how age-associated changes in the microbiome, shaped by the host and environment, contribute to development or severity of respiratory diseases. In this Article Collection, we are interested in manuscripts that broadly explore these topics, with emphasis on the following: 

• Chronic respiratory diseases and the airway microbiome (e.g., sinus microbiome composition, airway microbiome interactions)

• Chronic respiratory diseases and the gut microbiome (e.g., gut microbiome-lung axis in asthma; dietary habits on gut microbiome or GI morbidities in respiratory disease)

• Insights into host-microbiome interactions at the airway mucosa and via the gut microbiome-airway axis (e.g., modulation of type 2 immunity in the lungs by respiratory or gut microbiota; microbial metabolites and immune signaling; epigenetic regulation of host-microbiome interaction)

• Early-life development of the microbiome and asthma risk (e.g., early life microbial exposures and asthma susceptibility; household microbial exposures in early infancy)

• Health disparities focused on microbiome-targeted interventions or insights (e.g., intersectionality in health disparities and the combined impact of social determinants and microbiome in airway disease; microbiome-mediate effects of access to healthcare and airway disease outcomes)

• Novel technologies (e.g., single cell sequencing, integrated omics, microfluidics)

All manuscripts submitted to this Article Collection will undergo a full peer-review; the Guest Advisors for this Collection will not be handling the manuscripts (unless they are an Editorial Board member). Please review the journal scope and author submission instructions prior to submitting a manuscript.

Please submit your manuscript on our website, quoting the promo code VTXKB to indicate that your submission is for consideration in this Article Collection.

The deadline for submitting manuscripts is 17 May 2024. For questions about this Article Collection, including inquiries regarding discounts off of the article publishing charges, please contact Commissioning Editor Dr. MK Huffman at [email protected].

Guest Advisor

Emily Cope, Associate Professor, Northern Arizona University

[email protected]

Dr. Emily Cope is an Associate Professor of Biological Sciences at Northern Arizona University (NAU) and Assistant Director of the Pathogen and Microbiome Institute at NAU. Her research program focuses on the role of the microbiome, specifically microbiome-host interactions, in chronic and progressive diseases.

 

View all papers in this article collection


Call For Papers

Editor-in-Chief: Amrita Dosanjh, MD


To see where the Journal of Asthma and Allergy is indexed online view the Journal Metrics.

What is the advantage to you of publishing in the Journal of Asthma and Allergy?

  • It is an open access journal which means that your paper is available to anyone in the world to download for free directly from the Dove website.
  • Although the Journal of Asthma and Allergy receives many papers, unlike most traditional journals, your paper will not be rejected due to lack of space. We are an electronic journal and there are no limits on the number or size of the papers we can publish.
  • The time from submission to a decision being made on a paper can, in many journals, take some months and this is very frustrating for authors.  The Journal of Asthma and Allergy has a quicker turnaround time than this. Generally peer review is complete within 3-4 weeks and the editor’s decision within 2-14 days of this. It is therefore very rare to have to wait more than 6 weeks for first editorial decision.
  • Many authors have found that our peer reviewer’s comments substantially add to their final papers.

To recover our editorial and production costs and continue to provide our content at no cost to readers we charge authors or their institution an article publishing charge.

PubMed
The Journal of Asthma and Allergy is indexed on PubMed Central (title abbreviation: J Asthma Allergy). All published papers in this journal are submitted to PubMed for indexing straight away.

Become a Favored Author and receive real benefits
If you haven't already joined the Dove Press Favored Author Program I would encourage you to do so. Why? To receive real benefits like fast-tracking and a personal co-ordinator for your paper, as well as a discount on the publication processing fee.
Click here to go through to the Favored Author signup page.

Yours sincerely
Amrita Dosanjh, MD
Editor-in-Chief
Journal of Asthma and Allergy

Email: Editor-in-Chief